Probatebeta
Drug

Vinorelbine

As of the edition of 20 October 2026, Vinorelbine is a small molecule: marketed, first approved in 1989 (FR); acts on TUBB, TUBB1 and TUBB2A and 6 more.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 2004
Kind
Small molecule
Brand name
Navelbine
First approved
11 April 1989 (FR)
Approvals on record
3 in 3 regions
Holder of the most recent approval
Pierre Fabre Iberica S.A.; 2 holders in all
Registered trials
354, 59 stopped early
Disease areas
Cancer; Skin and connective tissue; Lungs and airways; Blood and lymph; Immune system; Urinary and reproductive

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Companies that need a new molecule because of this drug

8 company-target rows on route B because of this drug.

Companies on route B for this drug

In the product

8 company-target rows are on route B because of Vinorelbine.

See the 8 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.

Targets

GeneProteinUniProt
TUBB4ATubulin beta-4A chainP04350
TUBBTubulin beta chainP07437
TUBB4BTubulin beta-4B chainP68371
TUBB3Tubulin beta-3 chainQ13509
TUBB2ATubulin beta-2A chainQ13885
TUBB8Tubulin beta-8 chainQ3ZCM7
TUBB6Tubulin beta-6 chainQ9BUF5
TUBB2BTubulin beta-2B chainQ9BVA1
TUBB1Tubulin beta-1 chainQ9H4B7

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase not stated19632
Phase 1402717
Phase 22261191937
Phase 36527913
Phase 44300
All trials354

Who has held its approvals

CompanyRoleYears
GSKOriginator and Lead sponsor of trials1994 to now
Pierre FabreAcquired holder and Lead sponsor of trials2005 to now

Other drugs at TUBB4A

All of TUBB4A